INTT Stock Analysis: inTest | NYSE MKT
Semiconductor Equipment & Materials | NYSE MKT, USA | Market Cap: 197m USD | 12M Return: 86% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.59M
EPS Trend: -87.4%
Qual. Beats: 1
Rev. Trend: -57.7%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
inTEST Corporation (NYSE MKT: INTT) is a Mount Laurel, New Jersey-based provider of test and process technology solutions serving diverse end markets including semiconductor, automotive/electric vehicle, defense/aerospace, industrial, life sciences, and safety/security. Founded in 1981, the company operates through three reportable segments: Electronic Test (manipulators, docking hardware, tester interfaces, flying probe test systems, and automated test/programming services), Environmental Technologies (ThermoStream temperature management tools, thermal chambers and platforms, and ultra-cold storage solutions), and Process Technologies (induction heating systems and digital streaming/image capture solutions). Its customer base spans semiconductor manufacturers, third-party foundries, test and assembly providers, and OEMs across the U.S. and international markets.
Operating within the Semiconductor Materials & Equipment industry, inTEST supplies specialized equipment used during wafer-level and final test stages of chip production, a function that is essential to ensuring device reliability and yield. The semiconductor test equipment market is closely tied to wafer fab equipment investment cycles, and the companys diversified exposure to Auto/EV, defense, and life sciences end markets is a structural offset to the cyclicality of chip manufacturing capex.
- Semi test manipulator demand lifts Electronic Test segment revenue
- EV and defense diversification reduces single-cycle semi exposure
- Acquisition synergies expand gross margins across all three segments
| Net Income: 591k TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -6.48 > 1.0 |
| NWC/Revenue: 36.17% < 20% (prev 34.19%; Δ 1.98% < -1%) |
| CFO/TA -0.01 > 3% & CFO -1.53m > Net Income 591k |
| Net Debt (13.6m) to EBITDA (6.18m): 2.21 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.4m) vs 12m ago 1.99% < -2% |
| Gross Margin: 43.36% > 18% (prev 41.88%; Δ 1.47% > 0.5%) |
| Asset Turnover: 81.04% > 50% (prev 86.13%; Δ -5.09% > 0%) |
| Interest Coverage Ratio: 2.44 > 6 (EBIT TTM 922k / Interest Expense TTM 378k) |
| A: 0.29 (Total Current Assets 79.6m - Total Current Liabilities 35.8m) / Total Assets 150.8m |
| B: 0.29 (Retained Earnings 43.3m / Total Assets 150.8m) |
| C: 0.01 (EBIT TTM 922k / Avg Total Assets 149.4m) |
| D: 2.26 (Book Value of Equity 104.5m / Total Liabilities 46.3m) |
| Altman-Z'' = 5.25 = AAA |
| DSRI: 1.50 (Receivables 30.2m/21.2m, Revenue 121.1m/127.5m) |
| GMI: 0.97 (GM 41.88% / 43.36%) |
| AQI: 0.97 (AQ_t 0.38 / AQ_t-1 0.39) |
| SGI: 0.95 (Revenue 121.1m / 127.5m) |
| TATA: 0.01 (NI 591k - CFO -1.53m) / TA 150.8m) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 14.49 with a total of 157,281 shares traded. Over the past week, the price has changed by -20.25%, over one month by -7.29%, over three months by -1.76% and over the past year by +86.01%.
Current recommended Stop Loss: 12.00 (which is 17.2% or 1.7 ATR below the current price).
inTest has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy INTT.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.3 | 33.4% |
P/E Trailing = 392.5
P/E Forward = 29.1545
P/S = 1.6293
P/B = 1.8883
Revenue TTM = 121.1m USD
EBIT TTM = 922k USD
EBITDA TTM = 6.18m USD
Long Term Debt = 1.12m USD (from longTermDebt, last quarter)
Short Term Debt = 9.54m USD (from shortTermDebt, last quarter)
Debt = 26.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.98m
Net Debt = 13.6m USD (calculated: Debt 26.5m - CCE 12.9m)
Enterprise Value = 210.9m USD (197.3m + Debt 26.5m - CCE 12.9m)
Interest Coverage Ratio = 2.44 (Ebit TTM 922k / Interest Expense TTM 378k)
EV/FCF = -58.88x (Enterprise Value 210.9m / FCF TTM -3.58m)
FCF Yield = -1.70% (FCF TTM -3.58m / Enterprise Value 210.9m)
FCF Margin = -2.96% (FCF TTM -3.58m / Revenue TTM 121.1m)
Net Margin = 0.49% (Net Income TTM 591k / Revenue TTM 121.1m)
Gross Margin = 43.36% ((Revenue TTM 121.1m - Cost of Revenue TTM 68.6m) / Revenue TTM)
Gross Margin QoQ = 43.17% (prev 45.39%)
Tobins Q-Ratio = 1.40 (Enterprise Value 210.9m / Total Assets 150.8m)
Interest Expense / Debt = 1.43% (Interest Expense 378k / Debt 26.5m)
Taxrate = 19.24% (188k / 977k)
NOPAT = 745k (EBIT 922k * (1 - 19.24%))
Current Ratio = 2.22 (Total Current Assets 79.6m / Total Current Liabilities 35.8m)
Debt / Equity = 0.25 (Debt 26.5m / totalStockholderEquity, last quarter 104.5m)
Debt / EBITDA = 2.21 (Net Debt 13.6m / EBITDA 6.18m)
Debt / FCF = -3.81 (negative FCF - burning cash) (Net Debt 13.6m / FCF TTM -3.58m)
Total Stockholder Equity = 103.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.40% (Net Income 591k / Total Assets 150.8m)
RoE = 0.57% (Net Income TTM 591k / Total Stockholder Equity 103.1m)
RoCE = 0.88% (EBIT 922k / Capital Employed (Equity 103.1m + L.T.Debt 1.12m))
RoIC = 0.63% (NOPAT 745k / Invested Capital 118.4m)
WACC = 10.28% (E(197.3m)/V(223.8m) * Re(11.51%) + D(26.5m)/V(223.8m) * Rd(1.43%) * (1-Tc(0.19)))
Discount Rate = 11.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.22 | Cagr: 1.09%
[DCF] Fair Price = unknown (Cash Flow -3.58m)
EPS Correlation: -87.37 | EPS CAGR: -58.75% | SUE: 1.30 | # QB: 1
Revenue Correlation: -57.68 | Revenue CAGR: -2.57% | SUE: 1.33 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=+0.00% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=+0.00% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=0.47 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+677.8% | GrowthRev=+17.6%
EPS next Year (2027-12-31): EPS=0.63 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+35.7% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: +22% (up=4, down=2)